Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Good morning! Meta's elimination of fact-checking opens the door to misogynistic speech, Jane Fraser faces a test at Citi, ...

The company said that it would be recruiting more than a 1,000 highly-skilled team members to strengthen its digital strategy ...

Eli Lilly & Co. closed $199.24 short of its 52-week high ($972.53), which the company achieved on August 22nd.

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

The GCC, to be known as the Lilly Capability Centre India (LCCI), will be the company’s second centre in the country, ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...

The company further said it plans to employ around 1,000 to 1,500 highly-skilled professionals including technology engineers ...

Eli Lilly (LLY) has been one of the most searched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...